Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EnteroMedics Inflates Neuromod-Obesity Offering With ReShape Balloon

Executive Summary

The deal, worth $61m in cash and stock, will add ReShape's Dual Weight Loss Balloon to EnteroMedics' vBloc neurometabolic therapy and Gastric Vest System for the treatment of obesity.

Advertisement

Related Content

Market Intel: Intragastric Balloons And Other Innovations To Inflate Weight Loss Devices Market
Gastric Balloon-Makers Respond To US FDA Warning
US FDA Warns of Deaths Tied To Gastric Balloons
ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News
ReShape Duo Delivers Weight Loss In Sham-Controlled Pivotal Trial

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT121586

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel